| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335714 | Transfusion and Apheresis Science | 2010 | 6 Pages |
IntroductionIn a screening setting, maternal anti-HPA 1a antibody level has been found to be a good prognostic tool to identify newborns at risk for severe NAIT.AimIdentify the optimal MAIPA protocol for quantitation of anti-HPA 1a antibodies.Materials and methodsPlasma were analysed for anti-HPA 1a antibodies using different monoclonal antibodies, lyophilized or fresh platelets and MAIPA protocols.ResultsThe anti-HPA 1a antibody level varied significantly when different monoclonal antibodies were used. However, there was a strong correlation between maternal anti-HPA 1a antibody level and platelet count in the newborn. The sensitivity of the assay depended on the adopted MAIPA protocol.ConclusionConsistent tests results are of importance for the clinical impact of the test.
